Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
AstraZeneca
Johnson and Johnson
Colorcon
Merck
Chubb
Harvard Business School
Healthtrust

Generated: December 10, 2018

DrugPatentWatch Database Preview

Wyeth Pharms Company Profile

« Back to Dashboard

Summary for Wyeth Pharms
International Patents:273
US Patents:18
Tradenames:35
Ingredients:21
NDAs:37

Drugs and US Patents for Wyeth Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms ZOSYN piperacillin sodium; tazobactam sodium INJECTABLE;INJECTION 050684-002 Oct 22, 1993 AP RX Yes Yes 8,133,883 ➤ Sign Up Y ➤ Sign Up
Wyeth Pharms INDERAL propranolol hydrochloride TABLET;ORAL 016418-010 Oct 18, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Wyeth Pharms ZOSYN piperacillin sodium; tazobactam sodium INJECTABLE;INJECTION 050684-004 Oct 22, 1993 AP RX Yes Yes 8,133,883 ➤ Sign Up Y ➤ Sign Up
Wyeth Pharms Inc LODINE etodolac TABLET;ORAL 018922-004 Jul 29, 1993 DISCN Yes No ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc QUINIDEX quinidine sulfate TABLET, EXTENDED RELEASE;ORAL 012796-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Wyeth Pharms PROTONIX pantoprazole sodium FOR SUSPENSION, DELAYED RELEASE;ORAL 022020-001 Nov 14, 2007 RX Yes Yes 7,550,153*PED ➤ Sign Up Y ➤ Sign Up
Wyeth Pharms LO/OVRAL-28 ethinyl estradiol; norgestrel TABLET;ORAL-28 017802-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Wyeth Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997 6,419,958*PED ➤ Sign Up
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997 6,274,171*PED ➤ Sign Up
Wyeth Pharms OVRAL-28 ethinyl estradiol; norgestrel TABLET;ORAL-28 016806-001 Approved Prior to Jan 1, 1982 3,666,858 ➤ Sign Up
Wyeth Pharms PREMPRO estrogens, conjugated; medroxyprogesterone acetate TABLET;ORAL-28 020527-001 Nov 17, 1995 4,826,831 ➤ Sign Up
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-001 Oct 20, 1997 6,444,708*PED ➤ Sign Up
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-003 Jan 20, 1998 4,966,768*PED ➤ Sign Up
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997 4,535,186*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for WYETH PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg ➤ Subscribe 2005-11-03
➤ Subscribe Extended-release Tablets 37.5 mg, 75 mg and 150 mg ➤ Subscribe 2007-05-03
➤ Subscribe For Injection 12 g/1.5 g per vial (pharmacy bulk) ➤ Subscribe 2011-12-06
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2015-05-08
➤ Subscribe Tablets 0.09 mg/0.02 mg ➤ Subscribe 2007-10-05
➤ Subscribe Delayed-release Tablets 20 mg and 40 mg ➤ Subscribe 2004-02-02
➤ Subscribe Extended-release Tablets 50 mg and 100 mg ➤ Subscribe 2012-02-29

Supplementary Protection Certificates for Wyeth Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0416 Netherlands ➤ Sign Up 300416, 20170415, EXPIRES: 20220414
09/028 Ireland ➤ Sign Up PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/09/511/001-004 20090417
2011 00026 Denmark ➤ Sign Up PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
2016 00016 Denmark ➤ Sign Up PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
/2015 Austria ➤ Sign Up PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00095 Netherlands ➤ Sign Up PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0802183/01 Switzerland ➤ Sign Up PRODUCT NAME: BAZEDOXIFEN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58732 12.01.2010
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Covington
Boehringer Ingelheim
Queensland Health
Express Scripts
McKesson
AstraZeneca
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.